Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome.
Saved in:
| Title: | Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome. |
|---|---|
| Authors: | Dykens EM; Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, Tennessee, USA., Miller J; Division of Pediatric Endocrinology, University of Florida, College of Medicine, Gainesville, Florida, USA., Angulo M; Department of Pediatrics, Winthrop University Hospital, Mineola, New York, USA., Roof E; Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, Tennessee, USA., Reidy M; Ferring Pharmaceuticals Inc., Parsippany, New Jersey, USA., Hatoum HT; Hind T. Hatoum & Company, Chicago, Illinois, USA., Willey R; Ferring Pharmaceuticals Inc., Parsippany, New Jersey, USA., Bolton G; Ferring Pharmaceuticals Inc., Parsippany, New Jersey, USA., Korner P; Ferring Pharmaceuticals Inc., Parsippany, New Jersey, USA. |
| Source: | JCI insight [JCI Insight] 2018 Jun 21; Vol. 3 (12). Date of Electronic Publication: 2018 Jun 21 (Print Publication: 2018). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: eCollection Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2379-3708 |
|---|---|
| DOI: | 10.1172/jci.insight.98333 |
